Clinical TrialsSearch results
Number of results: 981
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 3 Study of ALXN2060 in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Ishioka Tatsunari
- 2020-12-04
Not yet recruiting
- A phase 3 clinical study to compare the efficacy and safety of AKP-022 with placebo in patients with uterine fibroids
- Heavy menstrual bleeding associated with uterine fibroid
- Hozumi Hiroyasu
- 2024-12-19
Other
- A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Primary Immune Thrombocytopenia
- Gandini Domenica
- 2021-10-29
Other
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
- Diffuse Large B-cell Lymphoma
- Ueda Eiji
- 2022-06-24
Completed
- A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Primary Immune Thrombocytopenia
- Gandini Domenica
- 2021-05-24
Completed
- A Phase 3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 12 Years and Older Who Have Completed Initial and Booster Immunization with SARS-CoV-2 Vaccines
- Prevention of infection due to SARS-CoV-2
- Inoguchi Akihiro
- 2023-02-28